Lee's Pharmaceutical Holdings Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Lee's Pharmaceutical Holdings hat ein Gesamteigenkapital von HK$1.6B und eine Gesamtverschuldung von HK$231.5M, wodurch sich der Verschuldungsgrad auf 14.2% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen HK$2.5B bzw. HK$921.4M. Lee's Pharmaceutical Holdings Das EBIT des Unternehmens beträgt HK$70.7M, so dass der Zinsdeckungsgrad 6.5 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von HK$195.0M.

Wichtige Informationen

14.2%

Verhältnis von Schulden zu Eigenkapital

HK$231.47m

Verschuldung

Zinsdeckungsgrad	6.5x
Bargeld	HK$194.99m
Eigenkapital	HK$1.63b
Gesamtverbindlichkeiten	HK$921.43m
Gesamtvermögen	HK$2.55b

Jüngste Berichte zur Finanzlage

Does Lee's Pharmaceutical Holdings (HKG:950) Have A Healthy Balance Sheet?

Apr 05

Recent updates

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

Sep 04

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Aug 07

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

May 21

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Dec 20

Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?

Mar 17

Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?

Feb 22

What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 29

What Type Of Shareholders Own The Most Number of Lee's Pharmaceutical Holdings Limited (HKG:950) Shares?

Jan 12

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 950Die kurzfristigen Aktiva des Unternehmens (HK$696.8M) übersteigen seine kurzfristigen Passiva (HK$632.6M).

Langfristige Verbindlichkeiten: 950Die kurzfristigen Vermögenswerte des Unternehmens (HK$696.8M) übersteigen seine langfristigen Verbindlichkeiten (HK$288.8M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 950Die Nettoverschuldung im Verhältnis zum Eigenkapital (2.2%) wird als zufriedenstellend angesehen.

Schulden abbauen: 950Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 5.4% auf 14.2% gestiegen.

Schuldendeckung: 950Die Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (56.2%).

Zinsdeckung: 950Die Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (6.5x Coverage) gut gedeckt.

Lee's Pharmaceutical Holdings Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Does Lee's Pharmaceutical Holdings (HKG:950) Have A Healthy Balance Sheet?

Recent updates

Investor sentiment improves as stock rises 16%

Board Member recently bought HK$66k worth of stock

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

First half 2024 earnings released: EPS: HK$0.11 (vs HK$0.027 in 1H 2023)

First half dividend of HK$0.02 announced

Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong Kong

Board Member recently bought HK$59k worth of stock

Board Member recently bought HK$117k worth of stock

Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive Director

Board Member recently bought HK$120k worth of stock

Board Member recently bought HK$61k worth of stock

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

Upcoming dividend of HK$0.01 per share

Board Member recently bought HK$130k worth of stock

Less than half of directors are independent

Final dividend of HK$0.01 announced

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022)

Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024

Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Board Member recently bought HK$123k worth of stock

New minor risk - Market cap size

Board Member recently bought HK$75k worth of stock

Investor sentiment improves as stock rises 15%

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Board Member recently bought HK$50k worth of stock

Board Member recently bought HK$113k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$347k worth of stock

Investor sentiment improves as stock rises 17%

Senior Adviser & Non-Executive Director recently bought HK$110k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$76k worth of stock

Investor sentiment improves as stock rises 18%

Price target decreased by 55% to HK$1.10

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023

First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022)

New minor risk - Market cap size

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director

Upcoming dividend of HK$0.01 per share at 1.3% yield

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021)

Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List

Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021)

Price target decreased to HK$1.80

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited to Report Q3, 2022 Results on Nov 17, 2022

Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa

Price target decreased to HK$1.80

Upcoming dividend of HK$0.01 per share

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on September 27, 2022

Second quarter 2022 earnings released: EPS: HK$0.014 (vs HK$3.59 in 2Q 2021)

Lee's Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 26, 2022

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Board Member recently bought HK$231k worth of stock

Lee's Pharmaceutical Holdings Limited Announces That Teglutik Obtains Drug Registration Certificate

Board Member recently bought HK$381k worth of stock

First quarter 2022 earnings released: EPS: HK$0.035 (vs HK$0.07 in 1Q 2021)

Lee's Pharmaceutical Holdings Limited's Natulan Obtains Drug Registration Certificate

Upcoming dividend of HK$0.031 per share

Lee's Pharmaceutical Holdings Limited to Report Q1, 2022 Results on May 26, 2022

Price target decreased to HK$4.85

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 19, 2022

Full year 2021 earnings released: EPS: HK$3.38 (vs HK$0.22 in FY 2020)

Lee's Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022

Price target decreased to HK$5.30

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Lee's Pharmaceutical Holdings Limited Obtains Approval from the Center for Drug Evaluation